Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Использование фиксированных комбинаций антигипертензивных средств – панацея в снижении сердечно-сосудистых осложнений?
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье обсуждаются вопросы приверженности больных антигипертензивной терапии, факторы, влияющие на приверженность лечению. Рассмотрены проблемы, обусловленные схемой медикаментозной антигипертензивной терапии, и пути их решения. Подчеркивается важность высокой приверженности лечению для достижения контроля артериального давления и снижения риска сердечно-сосудистых осложнений, а также необходимость более широкого применения фиксированных комбинаций антигипертензивных препаратов.
Ключевые слова: артериальная гипертензия, приверженность лечению, комбинированная терапия, фиксированные комбинации, бисопролол, гидрохлоротиазид.
Ключевые слова: артериальная гипертензия, приверженность лечению, комбинированная терапия, фиксированные комбинации, бисопролол, гидрохлоротиазид.
________________________________________________
The paper discusses compliance with antihypertensive therapy among patients and the factors influence their therapy adherence. It considers the problems resulting from an antihypertensive treatment regimen and ways for their solution.
The authors emphasize the importance of high therapeutic compliance to achieve blood pressure control and to reduce a cardiovascular risk and the need for wider use of fixed-dose antihypertensive combinations.
Key words: arterial hypertension, therapy adherence, combination therapy, fixed-dose combinations, bisoprolol, hydrochlorothiazide.
Полный текст
Список литературы
1. Hill M, Houston N. Adherence to antihypertensive therapy. Chapter 131: 390–2.
2. Yiannakopoulou I. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005; 12: 243–9.
3. Ho M, Steiner J, Rumsfeld J et al. Effect of Medication Noadherence on Hospitalization and Mortality Among Patients With Diabetes Mellitus. Arch Intern Med 2006; 166; 1836–41.
4. Breekveldt-Postma Р. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin 2008; 24: 121–7.
5. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomized trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996; 348: 383–6.
6. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994; 32: 214–26.
7. Конради А.О., Полуничева Е.В. Недостаточная приверженность к лечению артериальной гипертензии: причины и пути коррекции. Артериальная гипертензия. 2004; 10 (3): 137–43.
8. Waeber B, Burnier M, Brunner HR. How to improve adherence with prescribed treatment in hypertensive patients? J Cardiovasc Pharmacol 2000; 36 (Suppl. 3): S23–S26.
9. Fletcher A. Quality of life in the management of hypertension. Clin Exp Hypertens 1999; 21: 961–72.
10. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов (4-й пересмотр). Системные гипертензии 2010; 3: 5–26.
11. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 Trials. Am J Med 2009; 122 (3): 290–300.
12. Mourad J, Waeber B, Zinnad F et al. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens 2004; 22 (12): 2379–86.
13. Chapman A. Predictors of Adherence With Antihypertensive and Lipid-Lowering Therapy. Arch Intern Med 2005; 165: 1147–52.
14. Waeber B. Treatment strategy to control blood pressure optimally in hypertensive patients. Blood pressure 2001; 10: 62–73.
15. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manage Care 2000; 9 (Suppl. 9): 2–6.
16. Feldman RD, Zou GY, Vandervoort MK et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009; 53 (4): 646–53.
17. Egan BM. Fixed-dose combinations and hypertension control in community-based practices: application of the «keep-it-simple» principle. Hypertension 2009; 53 (4): 598–9.
18. Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical eventsin the VALUE Trial. Lancet 2004; 363 (9426): 2049–51.
19. Чазова И.Е., Ратова Л.Г. Фиксированная комбинация b-блокатора и диуретика в лечении больных артериальной гипертонией. Системные гипертензии. 2010; 4: 25–8.
20. Prisant LM, Neutel JM, Papademetriou V et al. Low-dose combination treatment for hypertension versus single-drug treatment-bisoprolol/hydrochlorothiazide versus amlodipine, enalapril and placebo: combined analysis of comparative studies. Am J Ther 1998; 5 (5): 313–21.
21. Frishman WH, Burris JF, Mroczek WJ et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995; 35 (2): 182–8.
22. Wallenius SH, Vainio KK, Korhonen MJ et al. Self-initiated modification of hypertension treatment in response to perceived problems. Ann Pharmacother 1995; 29: 1213–7.
23. Lip GY, Beevers GD. Doctors, nurses, pharmacists and patients. The rational evaluation and choice in hypertension (REACH) survey of hypertension delivery. Blood Pressure 1997; 6: 6–11.
24. Клиническая фармакология. Под ред. В.Г.Кукеса, 4-е изд. М.: ГЭОТАР-Медиа, 2008, с. 392–5.
25. Prisant LM, Weir MR, Frishman WH et al. Self Reported Sexual Dysfunction in Men and Women Treated With Bisoprolol, Hydrochlorothiazide, Enalapril, Amlodipine, Placebo, or Bisoprolol/Hydrochlorothiazide. J Clin Hypertens (Greenwich) 1999; 1 (1): 22–6.
26. Lee JY, Kusek JW, Greene PG et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am J Hypertens 1996; 9: 719–25.
27. Waeber B, Erne P, Saxenhofer H et al. Use of drugs with more than 24-hour duration of action. J Hypertens 1994; 12 (Suppl. 8): 67–71.
28. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH et al. Fixeddose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120 (8): 713–9.
2. Yiannakopoulou I. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005; 12: 243–9.
3. Ho M, Steiner J, Rumsfeld J et al. Effect of Medication Noadherence on Hospitalization and Mortality Among Patients With Diabetes Mellitus. Arch Intern Med 2006; 166; 1836–41.
4. Breekveldt-Postma Р. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin 2008; 24: 121–7.
5. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomized trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996; 348: 383–6.
6. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994; 32: 214–26.
7. Конради А.О., Полуничева Е.В. Недостаточная приверженность к лечению артериальной гипертензии: причины и пути коррекции. Артериальная гипертензия. 2004; 10 (3): 137–43.
8. Waeber B, Burnier M, Brunner HR. How to improve adherence with prescribed treatment in hypertensive patients? J Cardiovasc Pharmacol 2000; 36 (Suppl. 3): S23–S26.
9. Fletcher A. Quality of life in the management of hypertension. Clin Exp Hypertens 1999; 21: 961–72.
10. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов (4-й пересмотр). Системные гипертензии 2010; 3: 5–26.
11. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 Trials. Am J Med 2009; 122 (3): 290–300.
12. Mourad J, Waeber B, Zinnad F et al. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens 2004; 22 (12): 2379–86.
13. Chapman A. Predictors of Adherence With Antihypertensive and Lipid-Lowering Therapy. Arch Intern Med 2005; 165: 1147–52.
14. Waeber B. Treatment strategy to control blood pressure optimally in hypertensive patients. Blood pressure 2001; 10: 62–73.
15. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manage Care 2000; 9 (Suppl. 9): 2–6.
16. Feldman RD, Zou GY, Vandervoort MK et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009; 53 (4): 646–53.
17. Egan BM. Fixed-dose combinations and hypertension control in community-based practices: application of the «keep-it-simple» principle. Hypertension 2009; 53 (4): 598–9.
18. Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical eventsin the VALUE Trial. Lancet 2004; 363 (9426): 2049–51.
19. Чазова И.Е., Ратова Л.Г. Фиксированная комбинация b-блокатора и диуретика в лечении больных артериальной гипертонией. Системные гипертензии. 2010; 4: 25–8.
20. Prisant LM, Neutel JM, Papademetriou V et al. Low-dose combination treatment for hypertension versus single-drug treatment-bisoprolol/hydrochlorothiazide versus amlodipine, enalapril and placebo: combined analysis of comparative studies. Am J Ther 1998; 5 (5): 313–21.
21. Frishman WH, Burris JF, Mroczek WJ et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995; 35 (2): 182–8.
22. Wallenius SH, Vainio KK, Korhonen MJ et al. Self-initiated modification of hypertension treatment in response to perceived problems. Ann Pharmacother 1995; 29: 1213–7.
23. Lip GY, Beevers GD. Doctors, nurses, pharmacists and patients. The rational evaluation and choice in hypertension (REACH) survey of hypertension delivery. Blood Pressure 1997; 6: 6–11.
24. Клиническая фармакология. Под ред. В.Г.Кукеса, 4-е изд. М.: ГЭОТАР-Медиа, 2008, с. 392–5.
25. Prisant LM, Weir MR, Frishman WH et al. Self Reported Sexual Dysfunction in Men and Women Treated With Bisoprolol, Hydrochlorothiazide, Enalapril, Amlodipine, Placebo, or Bisoprolol/Hydrochlorothiazide. J Clin Hypertens (Greenwich) 1999; 1 (1): 22–6.
26. Lee JY, Kusek JW, Greene PG et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am J Hypertens 1996; 9: 719–25.
27. Waeber B, Erne P, Saxenhofer H et al. Use of drugs with more than 24-hour duration of action. J Hypertens 1994; 12 (Suppl. 8): 67–71.
28. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH et al. Fixeddose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120 (8): 713–9.
Авторы
О.Д.Остроумова*, Т.Ф.Гусева, О.В.Бондарец
ГОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова
*ostroumova.olga@mail.ru
ГОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова
*ostroumova.olga@mail.ru
________________________________________________
O.D.Ostroumova*, T.F.Guseva, O.V.Bondarets
*ostroumova.olga@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.